![Anthony Manning](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 10 108 $ in data 31/05/2026
Attualmente, Anthony M. Manning è presidente dell'Institute For Biomedical Entrepreneurship, Inc. e direttore scientifico di Momenta Pharmaceuticals, Inc. Il Dr. Manning è anche nel consiglio di amministrazione di Palatin Technologies, Inc. Il Dr. Manning ha precedentemente ricoperto la posizione di SVP-Research & Preclinical Development presso Aileron Therapeutics, Inc., Vice Presidente & Head-Autoimmune Diseases Research presso Biogen, Inc., Head-Research presso Celgene Corp., Vice Presidente & Global Head-Inflammation presso Roche Pharmaceuticals, Inc., Principal presso Signal Pharmaceuticals, Inc. e Vice Presidente presso Pharmacia Corp. Ha ricevuto un dottorato dall'Università di Otago.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/06/2025 | 721 ( 0,04% ) | 10 108 $ | 31/05/2026 | |
| 29/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 25/07/2023 |
Institute For Biomedical Entrepreneurship, Inc. | Fondatore | - |
| Società | Posizione | Fine |
|---|---|---|
| REIN THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2013 |
| BIOGEN INC. | Corporate Officer/Principal | 01/04/2011 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Corporate Officer/Principal | 01/08/2007 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Corporate Officer/Principal | 01/01/2002 |
| MOMENTA PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Palatin Technologies, Inc.
 Palatin Technologies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines based on molecules for the modulation of melanocortin receptor system | Health Technology |
Signal Pharmaceuticals, Inc.
 Signal Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research focused on the discover of new drugs | Commercial Services |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
Rein Therapeutics, Inc.
 Rein Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops stapled peptide drugs | Health Technology |
University of Otago
 University of Otago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
Institute For Biomedical Entrepreneurship, Inc. | |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
